[EN] PYRADAZINE COMPOUNDS AS GSK-3 INHIBITORS<br/>[FR] COMPOSES DE PYRADAZINE UTILES COMME INHIBITEURS DE GSK-3
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2004035588A1
公开(公告)日:2004-04-29
The present invention relates generally to inhibitors of the kinases, such as GSK3, and more particularly to fused pyradazine compounds according to formula (I) and methods of their use.
本发明通常涉及激酶抑制剂,如GSK3,更具体地涉及根据式(I)的融合吡啶并嘧啶化合物及其使用方法。
C–H Activation at a Bidentate Ligand Coordinated to Palladium(II) – an Electrophilic Attack Supported by an External Base
n-4-yl)pyridines undergo C–H activation at the phenyl ring in the ortho position to the amine nitrogen atom when reacted with (PhCN)2PdCl2 and finally form N,N,C-coordinated palladium(II) complexes in high yields. Five differently substituted complexes were synthesized and characterized by spectroscopy and X-ray structure analysis. The reaction mechanism for the formation of these complexes was elucidated
2-(2-Phenylaminopyrimidin-4-yl) 吡啶与 (PhCN)2PdCl2 反应时,在苯环胺氮原子邻位发生 C-H 活化,最终形成 N,N,C 配位钯 (II) ) 高产率的配合物。合成了五种不同取代的配合物,并通过光谱学和 X 射线结构分析对其进行了表征。通过动力学实验阐明了形成这些配合物的反应机理,从而可以计算出配合物形成的活化参数。
[EN] PYRAZOLOPARIDAZINE DERIVATIVES<br/>[FR] DERIVES DE PYRAZOLOPARIDAZINE
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2003051886A1
公开(公告)日:2003-06-26
Fused pyradazine derivatives, which are useful as CDK inhibitors are described herein. The described invention also includes methods of making such fused pyradazines derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.
The present invention relates generally to inhibitors of the kinases, such as GSK3, and more particularly to fused pyradazine compounds and methods of their use.
本发明通常涉及抑制激酶的抑制剂,例如GSK3,更具体地涉及融合嘧啶二氮杂环化合物及其使用方法。
Pyrazolopyridazine derivatves
申请人:Badiang G Jennifer
公开号:US20050090507A1
公开(公告)日:2005-04-28
Fused pyradazine derivatives, which are useful as CDK inhibitors are described herein. The described invention also includes methods of making such fused pyradazines derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.